Crinetics Pharmaceuticals Inc Q4 2020 Earnings Call Transcript - Thomson StreetEvents

Crinetics Pharmaceuticals Inc Q4 2020 Earnings Call Transcript

Crinetics Pharmaceuticals Inc Q4 2020 Earnings Call Transcript - Thomson StreetEvents
Crinetics Pharmaceuticals Inc Q4 2020 Earnings Call Transcript
Published Mar 30, 2021
Published Mar 30, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of CRNX.OQ earnings conference call or presentation 30-Mar-21 8:30pm GMT

  
Report Type:

Transcript

Source:
Company:
Crinetics Pharmaceuticals Inc
Ticker
CRNX.OQ
Time
8:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Daniel G. Wolle - JPMorgan Chase & Co, Research Division - Analyst : This is Daniel for Jessica Fye. First, starting maybe with PATHFNDR-1. Is there a washout period after the screening period right before the 9-month treatment period is initiated?


Question: Daniel G. Wolle - JPMorgan Chase & Co, Research Division - Analyst : Got it. Okay. And then regarding the rescue criteria definition, is it dependent on the 2 consecutive IGF-1 greater than equal to 1.3x upper limit of normal and exasperation of symptoms? Or is it just failure on the 2 consecutive IGF-1 scores? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 30, 2021 / 8:30PM, CRNX.OQ - Q4 2020 Crinetics Pharmaceuticals Inc Earnings Call


Question: Daniel G. Wolle - JPMorgan Chase & Co, Research Division - Analyst : Okay. And then for PATHFNDR-2, given that these patients are not well controlled, does it make sense to go against placebo? Why not an active agent in the control arm to create a stronger efficacy profile for paltusotine?


Question: Daniel G. Wolle - JPMorgan Chase & Co, Research Division - Analyst : Got it. Okay. And the last one, what's the rationale for PATHFNDR's -- sorry, that has been answered. But the other question is given the shorter duration of treatment period for PATHFNDR-2, how come data is still reading out in 2023 along with PATHFNDR-1, which has a longer treatment period?

Table Of Contents

Crinetics Pharmaceuticals Inc to Discuss CRN04894 Phase 1 Multiple-Ascending Dose Data Call Transcript – 2022-05-25 – US$ 54.00 – Edited Transcript of CRNX.OQ conference call or presentation 25-May-22 12:00pm GMT

Crinetics Pharmaceuticals Inc To Discuss Results From MAD Cohorts Of The Phase 1 Trial Of CRN04777 Corporate Call Transcript – 2022-03-30 – US$ 54.00 – Edited Transcript of CRNX.OQ conference call or presentation 30-Mar-22 8:30pm GMT

Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript – 2022-01-12 – US$ 54.00 – Edited Transcript of CRNX.OQ presentation 12-Jan-22 9:30pm GMT

Crinetics Pharmaceuticals Inc CRN04777 Phase 1 Program Results Call Transcript – 2021-09-15 – US$ 54.00 – Edited Transcript of CRNX.OQ conference call or presentation 15-Sep-21 8:30pm GMT

Crinetics Pharmaceuticals Inc Review CRN04894 Single Ascending Dose Results Call Transcript – 2021-08-10 – US$ 54.00 – Edited Transcript of CRNX.OQ conference call or presentation 10-Aug-21 8:30pm GMT

Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript – 2021-01-13 – US$ 54.00 – Edited Transcript of CRNX.OQ presentation 13-Jan-21 9:30pm GMT

Crinetics Pharmaceuticals, Inc. - Special Call Transcript – 2020-11-20 – US$ 54.00 – Edited Transcript of CRNX.OQ conference call or presentation 20-Nov-20 4:00pm GMT

Crinetics Pharmaceuticals Inc Review Of Phase 2 Paltusotine Results Call Transcript – 2020-10-26 – US$ 54.00 – Edited Transcript of CRNX.OQ conference call or presentation 26-Oct-20 12:00pm GMT

Crinetics Pharmaceuticals, Inc. - Special Call Transcript – 2020-04-07 – US$ 54.00 – Edited Transcript of CRNX.OQ conference call or presentation 7-Apr-20 12:00pm GMT

Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript – 2020-01-15 – US$ 54.00 – Edited Transcript of CRNX.OQ presentation 15-Jan-20 11:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Crinetics Pharmaceuticals Inc Q4 2020 Earnings Call Transcript" Mar 30, 2021. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2020-Crinetics-Pharmaceuticals-Inc-Earnings-Call-T14636932>
  
APA:
Thomson StreetEvents. (2021). Crinetics Pharmaceuticals Inc Q4 2020 Earnings Call Transcript Mar 30, 2021. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2020-Crinetics-Pharmaceuticals-Inc-Earnings-Call-T14636932>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.